A Phase 2 interventional study of CF101 and Placebo control in Rheumatoid Arthritis, sponsored by Can-Fite BioPharma. Completed at 5 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-05-24.
Sponsored by Can-Fite BioPharma · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 139 studies in Arthritis, Rheumatoid with a site in Bulgaria — 3 open to participants now, 7 under way, 1 of them phase 3. Arthritis, Rheumatoid · Bulgaria.
Among the 139 studies in Arthritis, Rheumatoid with a site in Bulgaria, this one is the 123rd largest by enrollment of the 136 interventional ones that give a count, is one of 8 that started in 2010, is one of 65 in phase 2, and was the 31st registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.
Browse Arthritis, Rheumatoid studies →3 of the 139 studies in Arthritis, Rheumatoid with a site in Bulgaria are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Bulgaria, United States, Argentina and 14 more countries
Ages 18+
Artiva Biotherapeutics, Inc. · Sites in Bulgaria, United States, Brazil and 8 more countries
Ages 18+
SynAct Pharma Aps · Sites in Bulgaria, United States, Denmark and 2 more countries
Ages 18+
A study can be open while its sites in Bulgaria have not opened yet or have stopped. Only those recruiting at a site in Bulgaria →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
139 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 67 · Phase 3 57 · Phase 4 3
First in 2005; this study’s year is marked. 8 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 79 is below the median of 95 across 2,221 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 398 across the 136 interventional studies, 351 across the 3 observational. Of the 132 that completed or were terminated, 103 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
139 of 139 have an industry lead sponsor. The 10 most frequent:
Can-Fite BioPharma is the lead sponsor of 22 studies on the registry; 5 are open to participants now.
Can-Fite BioPharma has 4 studies filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
2 of the studies in Arthritis, Rheumatoid with a site in Bulgaria that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06754462Immunovant Sciences GmbHA Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis | 2027-09 |
| NCT07276581AstraZenecaA Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis | 2027-11-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 139 studies in Arthritis, Rheumatoid with a site in Bulgaria, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial will test the hypothesis that the administration of CF101, a novel anti-inflammatory agent, to patients with rheumatoid arthritis and high A3AR expression at baseline will relieve signs and symptoms of the disease.
This will be a multi-center, randomized, double-blind, parallel-group, placebo-controlled, study in which patients with active RA and high A3AR expression at baseline will be randomized to the addition of either CF101 1.0 mg or placebo given orally q12h for 12 weeks. Screening examinations will occur within 1 month prior to dosing. Washout of other disease-modifying antirheumatic drugs (DMARDs), including biological agents, will occur prior to dosing; if washout is necessary, patients must re-qualify for inclusion following the washout. Doses of nonsteroidal anti-inflammatory drugs (NSAIDS) and corticosteroids must be stable for >=1 month prior to dosing and remain so during protocol participation. Disease activity will be assessed using swollen and tender joint counts, physician and patient global assessments (by visual analog scale, VAS), patient reported pain (by VAS), a Health Assessment Questionnaire (HAQ) Disability Index (DI), Westergren erythrocyte sedimentation rate (ESR, Screening, Weeks 0 and12), and C-reactive protein (CRP) levels. Assessments will take place at Screening, Baseline (Week 0), and at Weeks 2, 4, 8, and 12.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
piclidenoson (CF101) 1 mg tablet oral, Q12h for 12 weeks
Drug: CF101
placebo tablet to match the active, oral dosage, Q12h for 12 weeks
Drug: Placebo control
orally q12h
Also known as: IB-MECA
orally q12 hours
Also known as: Inactive pill
Number of Subjects Achieving an American College of Rheumatology 20 (ACR20) Response (20% Improvement)
ACR20 Response is defined as a 20% improvement from baseline in disease: 1. \>20% improvement in tender joint count (TJC), and 2. \>20% improvement in swollen joint count (SJC), and 3. \>20% improvement in at least 3 of following 5: 1. Physician global assessment (PGA), 2. Patient global assessment (PAGA), 3. Patient pain assessment (PPA), 4. Patient's assessment of physical function using Health Assessment Questionnaire (HAQ), and 5. Most improved response of ESR and CRP
Time frame: 12 weeks
Number of Subjects Achieving an ACR50 Response (50% Improvement)
ACR50 Response is defined as a 50% improvement from baseline in disease: 1. \>50% improvement in TJC, and 2. \>50% improvement in SJC, and 3. \>50% improvement in at least 3 of following 5: 1. Physician global assessment (PGA), 2. Patient global assessment (PAGA), 3. Patient pain assessment (PPA), 4. Patient's assessment of physical function using Health Assessment Questionnaire (HAQ), and 5. Most improved response of ESR and CRP
Time frame: 12 weeks
Number of Subjects Achieving an ACR70 Response (70% Improvement)
ACR70 Response is defined as a 70% improvement from baseline in disease: 1. \>70% improvement in TJC, and 2. \>70% improvement in SJC, and 3. \>70% improvement in at least 3 of following 5: 1. Physician global assessment (PGA), 2. Patient global assessment (PAGA), 3. Patient pain assessment (PPA), 4. Patient's assessment of physical function using Health Assessment Questionnaire (HAQ), and 5. Most improved response of ESR and CRP
Time frame: 12 weeks
| Milestone | CF101 1mg | Placebo |
|---|---|---|
| Started | 42 | 37 |
| Completed | 37 | 34 |
| Not completed | 5 | 3 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Withdrawal by subject | 2 | 2 |
| Withdrew: Hospitalized and decided to stop | 1 | 0 |
| Withdrew: Noncomplience | 1 | 0 |
ACR20 Response is defined as a 20% improvement from baseline in disease: 1. \>20% improvement in tender joint count (TJC), and 2. \>20% improvement in swollen joint count (SJC), and 3. \>20% improvement in at least 3 of following 5: 1. Physician global assessment (PGA), 2. Patient global assessment (PAGA), 3. Patient pain assessment (PPA), 4. Patient's assessment of physical function using Health Assessment Questionnaire (HAQ), and 5. Most improved response of ESR and CRP
| Participants | CF101 1mg | Placebo |
|---|---|---|
| Number of Subjects Achieving an American College of Rheumatology 20 (ACR20) Response (20% Improvement) | 18 | 8 |
ACR50 Response is defined as a 50% improvement from baseline in disease: 1. \>50% improvement in TJC, and 2. \>50% improvement in SJC, and 3. \>50% improvement in at least 3 of following 5: 1. Physician global assessment (PGA), 2. Patient global assessment (PAGA), 3. Patient pain assessment (PPA), 4. Patient's assessment of physical function using Health Assessment Questionnaire (HAQ), and 5. Most improved response of ESR and CRP
| Participants | CF101 1mg | Placebo |
|---|---|---|
| Number of Subjects Achieving an ACR50 Response (50% Improvement) | 7 | 3 |
ACR70 Response is defined as a 70% improvement from baseline in disease: 1. \>70% improvement in TJC, and 2. \>70% improvement in SJC, and 3. \>70% improvement in at least 3 of following 5: 1. Physician global assessment (PGA), 2. Patient global assessment (PAGA), 3. Patient pain assessment (PPA), 4. Patient's assessment of physical function using Health Assessment Questionnaire (HAQ), and 5. Most improved response of ESR and CRP
| Participants | CF101 1mg | Placebo |
|---|---|---|
| Number of Subjects Achieving an ACR70 Response (70% Improvement) | 4 | 1 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CF101 1mg | — | 1/42 (2.4%) | 0/42 (0%) |
| Placebo | — | 1/37 (2.7%) | 0/37 (0%) |
| Event | CF101 1mg | Placebo |
|---|---|---|
| atrial fibrillation with uncontrolled ventricular responseCardiac disorders | 0/42 | 1/37 |
| PyodermaInfections and infestations | 1/42 | 0/37 |
| Age, Continuous(years) | CF101 1mg | Placebo | Total |
|---|---|---|---|
| Mean | 56.7 ± 9.87 | 61.7 ± 6.89 | 59 ± 8.92 |
| Sex: Female, Male(Participants) | CF101 1mg | Placebo | Total |
|---|---|---|---|
| Female | 32 | 32 | 64 |
| Male | 10 | 5 | 15 |
The record gives a start of Oct 2010, a primary completion of Dec 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2015, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: CF101